immunotherapy company with a proprietary platform technology applicable across a wide range of therapeutic areas
Centauri has raised €39M across 2 funding rounds from 3 investors, most recently a Series A round in Feb 2026. Based in London, UK; active in Healthtech. Data as of 6 Aug 2026.
Timing: too soon vs cohort gap · momentum up. Funding-only estimates, not predictions and not investment advice — see signals.
| Date |
|---|
| Stage |
|---|
| Amount |
|---|
| Investors |
|---|
| 2026-02-24 | Series A | €34M | Other investors,The AMR Action Fund | View deal → |
| 2025-07-29 | Other | €4.4M | Carb-X | View deal → |
